Boundless Bio
Update in progressBOLD (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Boundless Bio, Inc. is a clinical‑stage oncology company developing therapies that target oncogene-amplified cancer using extrachromosomal DNA–directed approaches. Its lead candidate, BBI‑940, is an ecDNA-directed therapeutic in Phase 1/2 for estrogen receptor–positive, HER2‑negative breast cancer and for triple‑negative breast cancer with the luminal AR subtype. Formerly Pretzel Therapeutics, the company changed its name in 2019. Incorporated in 2018 and based in San Diego, California.
Company score
- Sentiment
- -0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.44
- Governance
- -0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!